Skip to main content Skip to main content

Your Skin Shouldn’t Welt From a Scarf: New Data Offers Hope

Rhapsido, the first pill approved for friction-triggered hives, kept symptoms in check for a full year.

Your Skin Shouldn’t Welt From a Scarf: New Data Offers Hope
Unsplash/Priscilla Du Preez

Cold-weather layers bring their own set of skin complaints, but for people with symptomatic dermographism, a type of chronic hives that flares from rubbing or pressure, a scratchy wool scarf or the strap of a heavy tote bag can leave raised, itchy welts behind. New one-year results presented at the American College of Allergy, Asthma & Immunology’s annual meeting show that the twice-daily pill Rhapsido kept those symptoms in check for the long haul, according to HCPLive.

Rhapsido, or remibrutinib, is a twice-daily pill that blocks a pathway (BTK) that signals immune cells to release histamine, the chemical that sets off hives and itch. It was first approved for chronic hives with no known trigger, and in October the FDA approved it for adults with dermographism that antihistamines don’t control, making it the first treatment cleared for that type.

The new data comes from RemIND, a study of 362 adults with trigger-based hives that antihistamines weren’t controlling. To measure results, researchers used trigger tests, which recreate a person’s trigger in the office to see whether hives still appear. In the dermographism group, about 42 percent of people on Rhapsido responded fully or partly by the first week, compared with about 19 percent on a placebo. A year in, about 47 percent of those who started on Rhapsido were still responding.

People who began on the placebo and switched to Rhapsido at the six-month mark caught up quickly, with about 48 percent responding at one year. Evanston, IL allergist-immunologist Giselle Mosnaim, MD, who led the study, told HCPLive she credits the pill’s fast onset for that.

The study also followed two other types of trigger-based hives, cold urticaria, which flares with cold air or water, and cholinergic urticaria, which flares with sweat and body heat. Rhapsido isn’t approved for either one yet, though Novartis says it plans more regulatory filings. After a year, 83 percent of people with cold hives who started on Rhapsido responded, along with about 58 percent of those with sweat-triggered hives. Mosnaim said the cold hives results were especially exciting but that researchers are still learning why responses differ by type.

According to Novartis, the pill was well tolerated through the full year, with a safety profile in line with earlier studies. In those earlier trials, the most common side effects included headache, cold-like symptoms such as a stuffy nose or sore throat and minor bleeding like bruising or tiny red spots on the skin.

Mosnaim noted that second-generation antihistamines had been the only option for trigger-based hives, adding, “For many patients, this treatment was not enough.” If heavier layers and colder air have your skin flaring, bring a list of your triggers to your next appointment and ask about your treatment options, including whether Rhapsido is a good fit. Our FAQ on the pill covers what to know before you start.

FIND A DOCTOR

Find a NewBeauty "Top Beauty Doctor" Near you

Filter doctors by location and specialty
NewBeauty Magazine Cover
NEWBEAUTY

Give the Gift of Luxury

GIVE A SUBSCRIPTION